Receiving FDA Orphan Drug Designation is a significant positive development for biotech and pharmaceutical companies. It not only provides regulatory and financial incentives but also enhances the company's reputation and product credibility. This designation is likely to increase investor confidence in Creative Medical Technology Holdings, leading to a potential rise in stock price in the short term.